Compare DexCom, Inc. (DXCM) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Manchester United PLC — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Manchester United PLC trades at $20.52 (market cap $3.51B). The key difference: DexCom, Inc. is far larger — about 9.1× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Manchester United PLC for 109 Days on average.
| DXCM | MANU | |
|---|---|---|
Market Cap | $31.86B | $3.51B |
Volume | 3,607,070 | 412,769 |
Sector | Health | Media |
52-Week High | $92.34 | $24.19 |
52-Week Low | $54.84 | $15.20 |
Typical Hold Time | 62 Days | 109 Days |
Enterprise Value | $31.32B | $4.33B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Manchester United (MANU) trades at $20.51, up 1.28% with a bearish technical outlook. The company reported mixed Q4 2026 results, missing EPS estimates but beating revenue expectations. Despite posting a net loss of $33.02M in 2025, revenue grew to $666.51M. Analyst sentiment is divided with 40% buy ratings, while institutional ownership shows confidence with Gabelli Funds increasing its stake by 26.2% in Q1 2026.
MANU presents a speculative opportunity given its discounted valuation relative to franchise worth, but faces significant profitability challenges. The stock's upside depends on operational improvements and Champions League performance, while persistent losses and high debt levels remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
